FindTrial
Sign In

INCB057643

DRUG4 trials

Sponsors

Incyte Corporation

Conditions

Advanced MalignanciesET (Essential Thrombocythemia)Healthy VolunteersMetastatic CancerMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm Overlap SyndromeMyelofibrosisMyeloproliferative Neoplasm

Phase 1

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
TerminatedNCT02711137
Incyte CorporationSolid Tumors
Start: 2016-05-18End: 2019-02-13Updated: 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
TerminatedNCT02959437
Incyte CorporationAdvanced Malignancies, Metastatic Cancer, Solid Tumors
Start: 2017-02-27End: 2020-03-02Updated: 2025-10-21
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Active, not recruitingNCT04279847
Incyte CorporationET (Essential Thrombocythemia), Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myelodysplastic Syndrome +4
Start: 2021-02-23End: 2027-04-30Updated: 2026-04-01
A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants
CompletedNCT06941077
Incyte CorporationHealthy Volunteers
Start: 2025-05-12End: 2025-06-03Updated: 2025-06-11

Related Papers

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy
Blood2025-11-03
Safety and efficacy of bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients (pts) with relapsed or refractory myelofibrosis (r/r-MF) and other advanced myeloid neoplasms: A phase (Ph) 1 study.
Journal of Clinical Oncology2025-05-281 citations
Abstract 7184: Novel role of INCB057643, a bromodomain and extra-terminal (BET) protein inhibitor, in myeloid cell regulation and immunosuppressive tumor environment remodeling in myelofibrosis (MF)
Cancer Research2025-04-21
Abstract 7188: INCB057643, a bromodomain and extra-terminal (BET) protein inhibitor, improved bone marrow function and shifted megakaryopoiesis to erythropoiesis in patients with myeloproliferative neoplasms (MPNs)
Cancer Research2025-04-21
Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
Blood2024-11-053 citations
Machine Learning in Predicting Longitudinal Platelet Counts: Applications in Dose Optimization
Blood2024-11-05
Safety and efficacy of bromodomain and extra-terminal protein inhibitor INCB057643 monotherapy in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: A phase 1 study
Blood2024-11-05
Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.
Journal of Clinical Oncology2024-06-011 citations
Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
Blood2023-11-024 citations
P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY
HemaSphere2023-08-011 citations
Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.
Journal of Clinical Oncology2023-06-01
INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study
Blood2022-11-151 citations
Abstract CT215: A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103)
Cancer Research2021-07-011 citations
A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103)
Blood2020-11-043 citations
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Clinical Cancer Research2019-09-1677 citations
Abstract 5080: BET inhibitors INCB054329 and INCB057643 display significant activity in androgen-independent prostate cancer models
Cancer Research2017-07-012 citations